At least two startup companies were formed to develop her work: International BioImmune Systems, which did the lung cancer work, and later Neogenix (subsequently sold to Precision Medicine), the lead product of which is ensituximab, a monoclonal antibody raised against a set of tumor antigens identified by Hollinshead.
